Stockscreener 앱 받기
41.69
2.33%
0.95
시장 영업 전:
41.88
0.19
+0.46%
전일 마감가:
$40.74
열려 있는:
$41.06
하루 거래량:
4.21M
Relative Volume:
1.56
시가총액:
$10.83B
수익:
$2.29B
순이익/손실:
$677.90M
주가수익비율:
17.55
EPS:
2.3753
순현금흐름:
$779.77M
1주 성능:
-6.84%
1개월 성능:
-2.25%
6개월 성능:
+11.53%
1년 성능:
+8.88%
1일 변동 폭
$40.69
$41.83
1주일 범위
$39.71
$45.01
52주 변동 폭
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
41.69 | 10.58B | 2.29B | 677.90M | 779.77M | 2.3753 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2026-01-05 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-11-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-09-19 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 재개 | Barclays | Equal Weight |
| 2025-09-17 | 개시 | Goldman | Buy |
| 2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
Forecasting The Future: 11 Analyst Projections For Exelixis - Sahm
Is Improving Analyst Sentiment Reframing Exelixis (EXEL) Oncology Pipeline As A Core Valuation Anchor? - simplywall.st
Exelixis (EXEL) EVP Haley granted 40,459 RSUs vesting from 2027 - Stock Titan
Exelixis (NASDAQ: EXEL) CEO granted RSUs, gifts 100K shares - Stock Titan
Exelixis stock falls after rival Merck trial shows better results - Investing.com
RBC Capital Lowers Exelixis (EXEL) Price Target to $43 | EXEL St - GuruFocus
Royal Bank Of Canada Issues Pessimistic Forecast for Exelixis (NASDAQ:EXEL) Stock Price - MarketBeat
Why Exelixis (EXEL) Stands Out as a Leading Value Investment for Long-Term Growth - Bitget
Exelixis (NASDAQ:EXEL) Shares Down 9.4% After Analyst Downgrade - MarketBeat
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating - marketscreener.com
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth With A 7.05% Potential Upside - DirectorsTalk Interviews
Exelixis (NASDAQ:EXEL) Downgraded by Wall Street Zen to Buy - MarketBeat
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - Nasdaq
3 Reasons Exelixis Stock Could Deliver Market‑Beating Returns Over the Next Decade - The Motley Fool
Citigroup Inc. Sells 365,552 Shares of Exelixis, Inc. $EXEL - MarketBeat
EXEL PE Ratio & Valuation, Is EXEL Overvalued - Intellectia AI
EXEL Should I Buy - Intellectia AI
Exelixis Director Julie Smith Sells Over 106K Shares - TradingView
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 47,918 Shares - MarketBeat
Exelixis (NASDAQ: EXEL) EVP sells 47,918 shares in open trade - Stock Titan
Exelixis EVP Sells Shares Worth Over $2 Million - TradingView
Intech Investment Management LLC Grows Stake in Exelixis, Inc. $EXEL - MarketBeat
Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case - ChartMill
Is It Too Late To Consider Exelixis (EXEL) After Its Surging Share Price? - Yahoo Finance
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March 2026 - BioSpace
Exelixis Cancer Pipeline Progress Puts Focus On Valuation And Growth Potential - Yahoo Finance
EXEL (NASDAQ: EXEL) insider Dana T Aftab sells 29,873 shares for $1.32M - Stock Titan
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in March - Business Wire
Oncology Market Set to Nearly Triple: Here Are Five Companies Le - GuruFocus
Oncology Market Set to Nearly Triple: Here Are Five Companies Leading the Charge - PR Newswire
Responsive Playbooks and the EXEL Inflection - Stock Traders Daily
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - Yahoo Finance
Exelixis reports solid earnings – are new highs back on the table? - MSN
Exelixis (NASDAQ:EXEL) EVP Dana Aftab Sells 29,873 Shares - MarketBeat
Exelixis (EXEL) R&D EVP sells 29,873 shares at $44.35 - Stock Titan
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Leader With 8.11% Potential Upside - DirectorsTalk Interviews
Exelixis (EXEL) Q4 2025 Earnings Call Transcript - AOL.com
Vanguard Group Inc. Lowers Position in Exelixis, Inc. $EXEL - MarketBeat
Advisors Preferred LLC Purchases 33,344 Shares of Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Upgraded at Wall Street Zen - MarketBeat
Will Exelixis Inc. outperform its industry peersTrade Exit Report & AI Optimized Trading Strategy Guides - mfd.ru
Exelixis (NASDAQ:EXEL) Director Jack Wyszomierski Sells 99,574 Shares - MarketBeat
Exelixis director Wyszomierski sells $4.38 million in stock By Investing.com - Investing.com UK
Exelixis director Wyszomierski sells $4.38 million in stock - Investing.com
Exelixis (EXEL) director sells 99,574 shares after option exercise - Stock Titan
Published on: 2026-02-21 01:41:50 - mfd.ru
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026 - Nasdaq
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.11%
6.00%
자본화:
|
볼륨(24시간):